JNJ: Strong Innovative Medicine Drives Guidance Raise but Mixed MedTech Keeps Risk/Reward Balanced, Supporting Hold Rating

In a report released today, Rick Wise from Stifel Nicolaus maintained a Hold rating on Johnson & Johnson, with a price target of $260.00.

TipRanks Welcomes a New ETF – NYSE:RANK

• TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
• RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

Rick Wise has given his Hold rating due to a combination of factors, balancing JNJ’s strong pharmaceutical momentum against more mixed MedTech trends and valuation considerations. He notes that second-quarter results were solid overall, with revenue and earnings beating expectations, largely thanks to exceptional growth in key Innovative Medicine products that underpin raised full-year guidance.

At the same time, Wise highlights that MedTech revenue modestly lagged forecasts and that divisional performance was uneven, particularly in cardiovascular segments such as electrophysiology and Abiomed, where growth slowed and visibility is limited. Taken together, the strength and improving outlook of the Innovative Medicine business are partially offset by softer MedTech dynamics and unclear broader read-throughs, leading him to conclude that risk and reward appear balanced at current levels, supporting a Hold stance on JNJ.

In another report released on July 10, Bank of America Securities also reiterated a Hold rating on the stock with a $263.00 price target.